“These findings are important because previous studies that looked at weight trajectories didn’t consider how patterns of weight gain/stability/loss might help signal that dementia is potentially imminent,” explained corresponding author Rhoda Au, Ph.D., professor of anatomy and neurobiology.
Through the Framingham Heart Study, a group of participants was followed for 39 years and their weight was measured approximately every 2-4 years. The researchers compared different weight patterns (stable, gain, loss) among those who did and did not become demented.
They found the overall trend of declining BMI was associated with a higher risk of developing dementia. However, after further exploration, they found a subgroup with a pattern of initial increasing BMI followed by declining BMI, both occurring within midlife, which appeared to be central to the declining BMI-dementia association.
Au points out that for individuals, family members, and primary care physicians, it is relatively easy to monitor weight. “If after a steady increase in weight that is common as one gets older, there is an unexpected shift to losing weight post midlife, it might be good to consult with one’s healthcare provider and pinpoint why. There are some potential treatments emerging where early detection might be critical in the effectiveness of any of these treatments as they are approved and become available,” she adds.
The researchers hope this study will illustrate that the seeds for dementia risk are being sowed across many years, likely even across the entire lifespan. “Dementia is not necessarily inevitable and monitoring risk indicators such as something as easy to notice as weight patterns, might offer opportunities for early intervention that can change the trajectory of disease onset and progression.”
These findings appear online in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
Funding for this study was provided by the Non-profit Central Research Institute Fund of Chinese Academic of Medical Science (2021-JKCS-023), the Framingham Heart Study’s National Heart, Lung, and Blood Institute contract (N01-HC-25195), the National Institute on Aging (AG016495, AG008122, AG033040, AG062109, AG049810, AG054156, AG062109, AG068753), National Institute of Neurological Disorders and Stroke (R01-NS017950) and VMF-14-318524 from the Alzheimer’s Association and Pfizer.
